Clover Biopharmaceuticalsâ SCB-1019 Shows Positive Results for Older Adult and Elderly Cohort

MT Newswires Live06-18

Clover Biopharmaceuticalsâ (HKG:2197) phase 1 results for its bivalent RSV vaccine candidate SCB-1019 for older adult and elderly cohort, were positive and were consistent with the positive results in the young adult cohort from earlier this year, a Tuesday filing with the Hong Kong Exchange said.

The drugâs immunogenicity results were comparable or better as compared with other protein subunit RSV PreF vaccines.

The drugâs safety test results showed that the drug was generally well-tolerated without any serious adverse events indicating that the drug has a better and more favorable safety & reactogenicity profile as compared to other vaccines.

Price (HKD): $0.37, Change: $, Percent Change: %

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444481330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-18 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444481330","market":"hk","top_or_hot":-1,"title":"Clover Biopharmaceuticalsâ SCB-1019 Shows Positive Results for Older Adult and Elderly Cohort","media":"MT Newswires Live","content":"<html><body><p> Clover Biopharmaceuticalsâ (HKG:2197) phase 1 results for its bivalent RSV vaccine candidate SCB-1019 for older adult and elderly cohort, were positive and were consistent with the positive results in the young adult cohort from earlier this year, a Tuesday filing with the Hong Kong Exchange said. </p><p>The drugâs immunogenicity results were comparable or better as compared with other protein subunit RSV PreF vaccines. </p><p>The drugâs safety test results showed that the drug was generally well-tolerated without any serious adverse events indicating that the drug has a better and more favorable safety &amp; reactogenicity profile as compared to other vaccines. </p><p>Price (HKD): $0.37, Change: $, Percent Change: %</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharmaceuticalsâ SCB-1019 Shows Positive Results for Older Adult and Elderly Cohort</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharmaceuticalsâ SCB-1019 Shows Positive Results for Older Adult and Elderly Cohort\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 20:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clover Biopharmaceuticalsâ (HKG:2197) phase 1 results for its bivalent RSV vaccine candidate SCB-1019 for older adult and elderly cohort, were positive and were consistent with the positive results ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2444481330","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444481330","pubTimestamp":1718712222,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clover Biopharmaceuticals  phase 1 results for its bivalent RSV vaccine candidate SCB-1019 for older adult and elderly cohort, were positive and were consistent with the positive results in the young adult cohort from earlier this year, a Tuesday filing with the Hong Kong Exchange said. The drugs immunogenicity results were comparable or better as compared with other protein subunit RSV PreF vaccines. The drugs safety test results showed that the drug was generally well-tolerated without any serious adverse events indicating that the drug has a better and more favorable safety & reactogenicity profile as compared to other vaccines. Price : $0.37, Change: $, Percent Change: %","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4526":"热门中概股","BK4588":"碎股","BK1161":"生物科技","BK4023":"应用软件","02197":"三叶草生物-B","HKD":"尚乘数科","BK4585":"ETF&股票定投概念"},"translate_title":"Clover Biopharmaceuticals的SCB-1019在老年人和老年人队列中显示出积极的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"02197":0.9},"content_text":"Clover Biopharmaceuticalsâ (HKG:2197) phase 1 results for its bivalent RSV vaccine candidate SCB-1019 for older adult and elderly cohort, were positive and were consistent with the positive results in the young adult cohort from earlier this year, a Tuesday filing with the Hong Kong Exchange said. The drugâs immunogenicity results were comparable or better as compared with other protein subunit RSV PreF vaccines. The drugâs safety test results showed that the drug was generally well-tolerated without any serious adverse events indicating that the drug has a better and more favorable safety & reactogenicity profile as compared to other vaccines. Price (HKD): $0.37, Change: $, Percent Change: %","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444481330"}

Clover Biopharmaceuticalsâ SCB-1019 Shows Positive Results for Older Adult and Elderly Cohort

Comments

Clover Biopharmaceuticalsâ SCB-1019 Shows Positive Results for Older Adult and Elderly Cohort